Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice

Basit Öğe Kaydı
dc.authorid0000-0001-7934-7039
dc.contributor.authorTural, Deniz
dc.contributor.authorArslan, Çağatay
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorAkar, Emre
dc.contributor.authorErman, Mustafa
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorErdem, Dilek
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2023-07-11T05:56:32Z
dc.date.available2023-07-11T05:56:32Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractThis 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly flat. The safety profile was consistent with previous reports, and no new safety signals were observed. Background: In this study, we report real-world results from the 5-year follow-up data of urothelial carcinoma patients treated with immune checkpoint blockade therapies (ICTs). Patients and Methods: Metastatic urothelial carcinoma patients treated with at least one course of ICT were included in the study. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS), progression-free survival (PFS), duration of treatment with ICT, and safety. Median follow-up, PFS, and OS were estimated by using the Kaplan-Meier method. Results: Data of 201 eligible patients were analyzed. The median age of the patients was 66 (37-86) years, and 156 (84.3%) were male. The majority of patients (94.6%) had Eastern Cooperative Oncology Group (ECOG) PS scores of 0 to 1 and primary tumor in the bladder was predominant (87.5%). The median follow-up time was 54 (1.15-65) months. The rate of complete response (CR) to ICT, partial response (PR) rate, and ORR were 10.4% (n = 21), 22.4% (n = 45), and 32.4% (n = 66), respectively. The median duration of response (DOR) was 34.8 months (95% confidence interval [CI], 29.2-42.1). Of the 66 patients who responded to treatment, 28 (42%) had an ongoing response at the time of the analysis. Median PFS and OS were 3.8 (2.6-5.8) months and 9.4 (7.4-11.4) months, respectively. The 5-year PFS and OS rates were 9.8% and 12.8%, respectively. Fifty-eight percent of patients experienced a treatment-related adverse event of any grade, and 33 (16.4%) patients had a grade 3 to 4 adverse event. Conclusion: This 5-year analysis of real-world data confirms the durable response and long-term survival with ICT in metastatic urothelial carcinoma patients.
dc.identifier.citationTural, D., Arslan, Ç., Selçukbiricik, F., Ölmez, Ö. F., Akar, E., Erman, M. ... Kılıçkap, S. (2023). Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice. Clinical Genitourinary Cancer, 21(3), 334-341. https://dx.doi.org/10.1016/j.clgc.2022.11.019
dc.identifier.doi10.1016/j.clgc.2022.11.019
dc.identifier.endpage341
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue3
dc.identifier.pmid36641357
dc.identifier.scopus2-s2.0-85146448744
dc.identifier.scopusqualityQ1
dc.identifier.startpage334
dc.identifier.urihttps://dx.doi.org/10.1016/j.clgc.2022.11.019
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11178
dc.identifier.volume21
dc.identifier.wos001009264100001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÖlmez, Ömer Fatih
dc.language.isoen
dc.publisherCIG Media Group
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectDurability of Antitumor Activity and Safety
dc.subjectImmune Checkpoint Blockade Therapies
dc.subjectLong-Term Survival
dc.subjectMetastatic Urothelial Carcinoma
dc.subjectOutcomes
dc.titleFive-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Olmez-Omer-2023.pdf
Boyut:
1.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu